Delhi High Court allows Dr. Reddy's to export Semaglutide
pre-market1 source ↓written by the desknot a recommendation
The Delhi High Court denied Novo Nordisk's request for an immediate stay on an order permitting Dr. Reddy's Laboratories to manufacture and export Semaglutide formulations to non-patent territories. The court acknowledged Novo Nordisk's concerns about potential infringement but emphasized the limited nature of the relief granted to Dr. Reddy's. This ruling may enhance Dr. Reddy's market position in regions without patent restrictions.
Not investment advice. For informational purposes only.